Content about Indianapolis

INDIANAPOLIS — John Johnson is bidding Eli Lilly adieu.

Johnson, who served as SVP and president of the drug maker's oncology business — whose portfolio includes Alimta (pemetrexed) and Gemzar (gemcitabine hydrochloride) — resigned, effective Jan. 28. Johnson is taking on the chief executive role at specialty biopharmaceutical company Savient, effective Jan. 31. Savient is best known for its chronic gout treatment Krystexxa (pegloticase), which received regulatory approval in September 2010.

INDIANAPOLIS — U.S. drug maker Eli Lilly and German drug maker Boehringer Ingelheim will collaborate to develop drugs for diabetes, the companies said Tuesday.

The agreement centers around investigative drugs currently in mid- to late-stage clinical development, including two oral drugs made by BI, BI10773 and linagliptin, and two basal insulin analogues made by Lilly, LY2605541 and LY2963016. The deal also includes options to develop and commercialize a Lilly monoclonal antibody.

INDIANAPOLIS — One month after announcing it would acquire a leader in molecular imaging development, Eli Lilly announced it has completed its acquisition of Avid Radiopharmaceuticals.

ORANGEBURG, N.Y. — Nice-Pak Products recently announced the transformation of its Mooresville, Ind., manufacturing plant into a “zero waste to landfill” facility — the plant now converts excess waste into energy that produces steam heat for Indianapolis.

INDIANAPOLIS — The U.S. District Court for the District of Delaware has upheld a patent held by Indianapolis-based drug maker Eli Lilly covering a chemotherapy drug, Lilly said Monday.

The case concerns a patent covering Alimta (pemetrexed) that expires in July 2016 and generic drug maker Teva Pharmaceutical Industries’ challenge to it.

INDIANAPOLIS and PHILADELPHIA Eli Lilly's acquisition of a leader in molecular imaging development could boost its Alzheimer's disease drug pipeline.

INDIANAPOLIS The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli Lilly and two other companies, the companies said Tuesday.

Lilly, Amylin Pharmaceuticals and Alkermes said the FDA issued them a complete response letter for their application for Bydureon (exenatide), a once-weekly version of the Type 2 diabetes drug Byetta. A complete response letter means that the FDA has completed review of a regulatory application, but issues remain that preclude approval.

INDIANAPOLIS Chip Ganassi Racing on Wednesday announced that GlaxoSmithKline’s Breathe Right brand will be placed on the nose of the team’s Target Indy car this weekend during the Peak Antifreeze and Motor Oil Indy 300 Chicagoland Speedway races.

Additionally, on Aug. 28, race fans will have the opportunity to meet two-time and reigning IZOD IndyCar Series champion Dario Franchitti, driver of the Target Indy car, on-site at the Breathe Right Advanced tent where free product samples will be made available.

INDIANAPOLIS The nation's largest retailer has teamed up with a drug company to provide an affordable insulin option for people with diabetes.

Lilly's Humulin will be offered by mid-September to Walmart pharmacy patients under the dual-branded name Humulin ReliOn, including 10 mL vials of Humulin R U-100, Humulin N and Humulin 70/30 formulations.

INDIANAPOLIS Allergy sufferers can save money and receive quality, convenient care by skipping the emergency room and instead visiting a retail-based or urgent-care clinic, according to a recent study.

The study conducted by HealthCore, WellPoint’s outcomes research subsidiary, found that patients can save anywhere from $50 to $400 in out-of-pocket costs per visit by skipping the ER and heading to a retail health- or urgent-care clinic when they are unable to see their primary care physician.